[1]Patent:WO2013/57468,2013,A1.Locationinpatent:Page/Pagecolumn23
[2]Patent:WO2010/70658,2010,A2.Locationinpatent:Page/Pagecolumn23-24
[3]Patent:US2011/263854,2011,A1.Locationinpatent:Page/Pagecolumn9-10
[1]Patent:US2011/263854,2011,A1
[2]OrganicProcessResearchandDevelopment,2001,vol.5,p.16-22
[1]Patent:US2011/263854,2011,A1
[2]Patent:WO2013/57468,2013,A1
[3]OrganicProcessResearchandDevelopment,2001,vol.5,p.16-22
Title: Frank Enseleit, et al. Darusentan, a selective endothelin A receptor antagonist, for the oral treatment of resistant hypertension. Ther Adv Cardiovasc Dis. 2010 Aug;4(4):231-40.
Title: Liang F, et al. Darusentan is a potent inhibitor of endothelin signaling and function in both large and small arteries. Can J Physiol Pharmacol. 2010 Aug;88(8):840-9.
Title: H H Dao, et al. Norepinephrine-induced aortic hyperplasia and extracellular matrix deposition are endothelin-dependent. J Hypertens. 2001 Nov;19(11):1965-73.
